论文部分内容阅读
目的分析肝动脉化疗栓塞(TACE)联合射频消融术(RFA)治疗原发性肝细胞癌(HCC)的临床疗效及安全性。方法 HCC患者76例,随机分为两组,对照组31例,采用肝切除术;观察组45例,采用TACE联合RFA治疗。比较两组患者治疗3个月后的甲胎蛋白(AFP)、癌胚抗原(CEA)、磷脂酰肌醇蛋白聚糖-3(GPC3)血清水平及2年的生存率,并记录并发症的发生情况。结果两组患者经治疗后血清中AFP、CEA、GPC3水平明显下降,治疗前、后比较差异有统计学意义(P<0.05),但两组问AFP、CEA、GPC3水平比较差异无统计学意义(P>0.05)。观察组2年生存率与对照组比较,差异无统计学意义(P>0.05)。两组患者术后3个月生活质量均比术前有所提高(P>0.05),并且观察组比对照组提高更明显[(8.82±0.98)比(7.04±1.24),P>0.05]。结论 TACE联合RFA能有效治疗HCC,疗效与肝切除术相当,但可以提高生活质量并减少手术创伤。
Objective To analyze the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) in the treatment of primary hepatocellular carcinoma (HCC). Methods 76 patients with HCC were randomly divided into two groups, control group of 31 cases, using hepatectomy; observation group of 45 patients, the use of TACE combined with RFA treatment. The serum levels of AFP, CEA, GPC3 and the 2-year survival rate of the two groups were compared after 3 months of treatment, and the complications What happened? Results Serum levels of AFP, CEA and GPC3 in both groups were significantly decreased after treatment (P <0.05), but the levels of AFP, CEA and GPC3 were not significantly different between the two groups (P> 0.05). The 2-year survival rate of the observation group compared with the control group, the difference was not statistically significant (P> 0.05). The quality of life at 3 months after operation in both groups was significantly higher than that before operation (P> 0.05), and the observation group was more obvious than the control group (8.82 ± 0.98 vs 7.04 ± 1.24, P> 0.05). Conclusion TACE combined with RFA can effectively treat HCC. The curative effect is equivalent to that of hepatectomy, but it can improve the quality of life and reduce the surgical trauma.